AbbVie's SWOT analysis: stock outlook amid Humira erosion and pipeline growth
AbbVie Inc (NYSE:ABBV)., a leading biopharmaceutical company, stands at a critical juncture as it navigates the loss of ...
Humira Holds Firm at 72% Market Share-AbbVie Fends Off Biosimilar Surge
Losing U.S. exclusivity in early 2023, Humira, the top-selling arthritis medication from AbbVie, let biosimilars from Amgen ( ...
AbbVie retains Humira market share above 70%: report
AbbVie (NYSE:ABBV) has managed to keep its market share for its bestselling arthritis therapy, Humira, above 70%, generic ...
AbbVie keeps Humira lead as biosimilar entry nears two-year mark
AbbVie (ABBV) continues to dominate the adalimumab market with 72% share in the U.S., despite biosimilar threats gaining ground. Read more here.
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
AbbVie executives said they have high hopes for Skyrizi and Rinvoq in the inflammatory bowel disease market after Humira ...
3 High-Yield Dividend Stocks to Buy in 2025
High-yield dividend stocks may not appeal to some investors. Three Motley Fool contributors have identified some especially great high-yield dividend stocks to buy in 2025 -- and all of them are big ...